Special articleUrgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19)
Abbreviations and Acronyms
COVID-19
coronavirus disease 19
DI-SCD
drug-induced sudden cardiac death
DI-TdP
drug-induced torsades de pointes
ECG
electrocardiogram
FDA
Food and Drug Administration
LQTS
long QT syndrome
PPE
personal protective equipment
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
Cited by (0)
Grant Support: This work was supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program.
Potential Competing Interests: Dr Ackerman is a consultant for Abbott, Audentes Therapeutics, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Invitae Corporation, LQT Therapeutics Inc, Medtronic, and MyoKardia. Drs Noseworthy, Friedman, and Ackerman and Mayo Clinic are involved in an equity/royalty relationship with AliveCor, Inc (not involved in this study). Dr Giudicessi reports no competing interests.
© 2020 Mayo Foundation for Medical Education and Research